Expert Interview
Discussing Incyte's Phase 3 results for Povorcitinib in Patients With Hidradenitis Suppurativa.
Ticker(s): INCYInstitution: UT Dell Medical School
- Board certified dermatologist and assistant profess at UT Dell Medical School.
- Serves as cheif of dermatology at Central Texas Veterans Health Care System.
- Clinical expertise in medical and surgical treatment of hidradenitis suppurativa and is the head of the Follicular Disorders Clinic in Austin.
- Completed her internship in pediatrics at St. Christopher’s Hospital for Children in Philadelphia followed by residency training in dermatology at Henry Ford Health System in Detroit.
How many patients do you manage with for Hidradenitis Suppurativa?
Added By: nikki_adminOn a scale from 1-10 (10 being extremely excited), how excited are you about the Phase 2 results for Povorcitinib?
Added By: nikki_adminNow that topline Phase 3 data is available, how would you describe your level of confidence in povorcitinib becoming a viable treatment option for moderate to severe HS?
Added By: slingshot_insightsWere you surprised by the consistency of efficacy across both STOP-HS1 and STOP-HS2 trials at both the 45 mg and 75 mg doses? Why or why not?
Added By: slingshot_insightsThe studies showed improvements in HiSCR50 and also deeper responses like HiSCR75 and skin pain reduction. How important are these endpoints to you in clinical practice?
Added By: slingshot_insightsGiven the safety profile and oral administration of povorcitinib, how do you see this treatment fitting into your current HS management approach—especially for patients who have failed biologics?
Added By: slingshot_insightsWith a potential regulatory submission underway, what factors would influence your willingness to adopt povorcitinib quickly after approval?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
